Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fero Industries, a company focused on diabetes prevention and treatments, has selected Canada-based PNP Pharmaceuticals as the exclusive global manufacturer of Sucanon, as part of its plans to introduce the drug into new markets.
Subscribe to our email newsletter
PNP Pharmaceuticals operates 48,000 square foot manufacturing facility in Canada.
Sucanon, an oral treatment for type-2 diabetes, is a member of a class of diabetic medications called insulin sensitizers.
According to pre-clinical and clinical studies, Sucanon lowers blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
Sucanon, which has been approved for prescription sale in China and Peru, is also approved as an OTC treatment in Mexico and is distributed under an exclusive agreement with Merck.
Fero Industries COO Luis Lopez said the addition of PNP Pharmaceuticals as the exclusive Sucanon manufacturer will immediately allow them to expand supply capabilities to meet current demands and satisfy the anticipated increase in product volume.